Last reviewed · How we verify
Radiopharmaceutical 18F-JK-PSMA-7
Radiopharmaceutical 18F-JK-PSMA-7 is a PSMA-targeted PET imaging agent Small molecule drug developed by ITEL Telecomunicazioni Srl. It is currently in Phase 3 development for PET imaging of PSMA-positive prostate cancer. Also known as: 18F-JK-PSMA-7.
18F-JK-PSMA-7 is a fluorine-18 labeled radiopharmaceutical that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.
18F-JK-PSMA-7 is a fluorine-18 labeled radiopharmaceutical that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors. Used for PET imaging of PSMA-positive prostate cancer.
At a glance
| Generic name | Radiopharmaceutical 18F-JK-PSMA-7 |
|---|---|
| Also known as | 18F-JK-PSMA-7 |
| Sponsor | ITEL Telecomunicazioni Srl |
| Drug class | PSMA-targeted PET imaging agent |
| Target | PSMA (prostate-specific membrane antigen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This radiopharmaceutical is a diagnostic imaging agent designed to target PSMA, a transmembrane protein highly expressed on prostate cancer cells. The fluorine-18 radiolabel enables PET imaging to detect and localize PSMA-positive lesions, facilitating tumor staging, restaging, and treatment planning in prostate cancer patients.
Approved indications
- PET imaging of PSMA-positive prostate cancer
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radiopharmaceutical 18F-JK-PSMA-7 CI brief — competitive landscape report
- Radiopharmaceutical 18F-JK-PSMA-7 updates RSS · CI watch RSS
- ITEL Telecomunicazioni Srl portfolio CI
Frequently asked questions about Radiopharmaceutical 18F-JK-PSMA-7
What is Radiopharmaceutical 18F-JK-PSMA-7?
How does Radiopharmaceutical 18F-JK-PSMA-7 work?
What is Radiopharmaceutical 18F-JK-PSMA-7 used for?
Who makes Radiopharmaceutical 18F-JK-PSMA-7?
Is Radiopharmaceutical 18F-JK-PSMA-7 also known as anything else?
What drug class is Radiopharmaceutical 18F-JK-PSMA-7 in?
What development phase is Radiopharmaceutical 18F-JK-PSMA-7 in?
What does Radiopharmaceutical 18F-JK-PSMA-7 target?
Related
- Drug class: All PSMA-targeted PET imaging agent drugs
- Target: All drugs targeting PSMA (prostate-specific membrane antigen)
- Manufacturer: ITEL Telecomunicazioni Srl — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for PET imaging of PSMA-positive prostate cancer
- Also known as: 18F-JK-PSMA-7